The company initiates the P-II trial, conducted in 2 parts evaluating the combination of Novavax’s COVID-19 vaccine NVX-CoV2373, quadrivalent influenza vaccine candidate & patented saponin-based Matrix-M adjuvant in adults aged 50-80yrs. Study plans to initiate enrolment of ~2300 patients across multiple sites in Australia & New Zealand
The primary & secondary objectives are to evaluate the safety, tolerability & immune responses to multiple formulations of CIC & influenza vaccine candidates
Initial findings are expected in mid-year 2023 & these data will support the P-III trials for combination candidates. Multiple regulatory bodies incl. the US FDA, EC & WHO have approved the COVID-19 vaccine, which is under review for additional indications & populations
Ref: PR Newswire | Image: Novavax
Related News:- Novavax’s Nuvaxovid Receives Expanded Authorization for COVID-19 in Canada
